Holen Sie sich die Stockscreener-App
8.6869
0.91%
-0.0731
Schlusskurs vom Vortag:
$8.76
Offen:
$8.7
24-Stunden-Volumen:
208.36K
Relative Volume:
0.11
Marktkapitalisierung:
$573.98M
Einnahmen:
$170.44M
Nettoeinkommen (Verlust:
$-193.88M
KGV:
-2.314
EPS:
-3.7541
Netto-Cashflow:
$-126.38M
1W Leistung:
-9.58%
1M Leistung:
-19.03%
6M Leistung:
-16.38%
1J Leistung:
-12.23%
1-Tages-Spanne:
$8.62
$8.86
1-Wochen-Bereich:
$8.60
$9.56
52-Wochen-Spanne:
$5.455
$16.19
Regenxbio Inc Stock (RGNX) Company Profile
Firmenname
Regenxbio Inc
Sektor
Branche
Telefon
240-552-8181
Adresse
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Compare RGNX vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
8.695 | 578.28M | 170.44M | -193.88M | -126.38M | -3.7541 |
VRTX
Vertex Pharmaceuticals Inc
|
522.04 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
799.73 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,000.06 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.54 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.27 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2025-02-11 | Herabstufung | Goldman | Buy → Neutral |
| 2025-02-07 | Fortgesetzt | Raymond James | Outperform |
| 2024-11-15 | Fortgesetzt | Morgan Stanley | Overweight |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-06-07 | Eingeleitet | Goldman | Buy |
| 2024-03-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-03-08 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-03-06 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-02-21 | Fortgesetzt | Raymond James | Outperform |
| 2023-11-01 | Eingeleitet | Stifel | Buy |
| 2023-06-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-06-23 | Eingeleitet | Berenberg | Buy |
| 2021-12-15 | Eingeleitet | Wedbush | Neutral |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-01-06 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2020-12-16 | Eingeleitet | UBS | Buy |
| 2020-06-25 | Fortgesetzt | BofA/Merrill | Buy |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-08-20 | Hochstufung | SVB Leerink | Underperform → Mkt Perform |
| 2019-06-18 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-06-14 | Fortgesetzt | Raymond James | Outperform |
| 2019-06-05 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-02-25 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-02-05 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2018-12-17 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-11-08 | Bestätigt | BofA/Merrill | Neutral |
| 2018-08-08 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-07-23 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-07-10 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-05-09 | Bestätigt | Barclays | Overweight |
| 2018-04-09 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-03-12 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2018-02-13 | Eingeleitet | Mizuho | Neutral |
| 2017-11-09 | Fortgesetzt | Morgan Stanley | Overweight |
Alle ansehen
Regenxbio Inc Aktie (RGNX) Neueste Nachrichten
REGENXBIO to present at two major healthcare investor conferences in September 2026 - Pluang
REGENXBIO to Participate in Upcoming Investor Conferences - marketscreener.com
This REGENXBIO Insider Increased Their Holding In The Last Year - 富途牛牛
QURE Or RGNX: Which Gene Therapy Was FDA Chief Really Warning About In Rare Disease Remarks? - Stocktwits
RGNX Stock: Clear Street Sees Potential Cash Risk From RGX-121 FDA Hold - Stocktwits
Regenxbio Stock Price Forecast. Should You Buy RGNX? - StockInvest.us
REGENXBIO Inc. (RGNX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Regenxbio’s Gene Therapy Faces Another FDA Setback in Hunter Syndrome - Yahoo Finance
REGENXBIO CTO Malzahn Craig Retains 81,960 Shares After Forfeiture on September 1, 2026 - kalkinemedia.com
REGENXBIO CFO Chan Mitchell Forfeits 4,902 Shares at $9.32 Each (NASDAQ: RGNX) - kalkinemedia.com
REGENXBIO CFO Mitchell Chan Reports Tax-Driven Share Withholding on RSU Vesting - Kalkine Media
How Regenxbio Inc. (RGNX) Affects Rotational Strategy Timing - Stock Traders Daily
REGENXBIO Faces FDA Clinical Hold on Hunter Syndrome Gene Therapy - Streetwise Reports
RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
People on the Move: Greg Ciongoli Joins REGENXBIO’s Board of Directors - BioBuzz
Regenxbio stock surges on director share purchases By Investing.com - Investing.com Nigeria
Regenxbio stock surges on director share purchases - Investing.com
Why is Regenxbio stock rallying today? - Investing.com
REGENXBIO : Initial Statement of Beneficial Ownership (Form 3) - marketscreener.com
H.C. Wainwright cuts Regenxbio stock price target on clinical hold - Investing.com
Regenxbio's FDA Hold Threatens Voucher Windfall, Analysts Slash Targets - finance.biggo.com
Regenxbio Hits Regulatory Roadblock After FDA Puts RGX-121 on Hold - Sahm
REGENXBIO Adds Greg Ciongoli to Board Ahead of Commercial Expansion - citybiz
RGNX Stock Slumps 25% on FDA Clinical Hold for RGX-121 Gene Therapy - Yahoo Finance
REGENXBIO says FDA places RGX-121 on clinical hold; BLA resubmission not expected soon - TradingView
FDA places clinical hold on Regenxbio’s gene therapy for Hunter Syndrome - kfgo.com
Regenxbio halts BLA resubmission for Hunter syndrome therapy By Investing.com - Investing.com Nigeria
Why Regenxbio Halted Its Gene Therapy Trial—and Why the Stock Is Tumbling - Barron's
REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights - Eastern Progress
REGENXBIO (NASDAQ:RGNX) Trading Down 3.9%Should You Sell? - MarketBeat
RGNX Q2 2026 Earnings: Gene Therapy Developer Posts 626% EPS SurpriseEBITDA Analysis - Vinanet
Sarepta Hits Fresh Hurdle As Court Revives Patent Lawsuit With Regenxbio Over Muscular Disorder Therapy - Stocktwits
Walleye Capital LLC Invests $2.44 Million in REGENXBIO Inc. $RGNX - MarketBeat
REGENXBIO (NASDAQ:RGNX) Rating Increased to Hold at Zacks Research - MarketBeat
Assenagon Asset Management S.A. Has $2.03 Million Position in REGENXBIO Inc. $RGNX - MarketBeat
REGENXBIO (RGNX) Pulls Back 2.29% to $10.66 — Gene Therapy Play Tests Key SupportPCR Moving Average - Vinanet
FDA Commissioner Refers To Rare Disease Drug With Associated Morbidity: Analysts Are Divided If Makary Meant Regenxbio Or Uniqure’s Experimental Therapy - Stocktwits
(RGNX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
HC Wainwright Has Pessimistic View of REGENXBIO Q3 Earnings - MarketBeat
REGENXBIO’s Multi-Catalyst Setup Is Hard To Ignore (Rating Upgrade) (NASDAQ:RGNX) - Seeking Alpha
H.C. Wainwright lowers Regenxbio stock price target on equity offering By Investing.com - Investing.com UK
RGNX Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
H.C. Wainwright lowers Regenxbio stock price target on equity offering - Investing.com
H.C. Wainwright Maintains Regenxbio(RGNX.US) With Buy Rating, Cuts Target Price to $23 - Moomoo
Dimensional Fund Advisors LP Increases Stock Position in REGENXBIO Inc. $RGNX - MarketBeat
RGNX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds - The National Law Review
Regenxbio Inc (RGNX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
RGNX STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Bank of America Securities Reaffirms Their Buy Rating on RegenXBio (RGNX) - The Globe and Mail
REGENXBIO (RGNX) Stock Drops Despite Profit Surprise And Longer Cash Runway - Sahm
Finanzdaten der Regenxbio Inc-Aktie (RGNX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Regenxbio Inc-Aktie (RGNX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Ciongoli Gregory Austin | Director |
Aug 26 '26 |
Buy |
9.14 |
49,196 |
449,706 |
64,628 |
| PAKOLA STEVE | Chief Medical Officer |
Jul 02 '26 |
Option Exercise |
7.86 |
2,161 |
16,985 |
215,170 |
| PAKOLA STEVE | Chief Medical Officer |
Jul 02 '26 |
Sale |
13.64 |
2,161 |
29,476 |
213,009 |
| PAKOLA STEVE | Chief Medical Officer |
Jul 01 '26 |
Option Exercise |
7.86 |
36,725 |
288,658 |
249,734 |
| PAKOLA STEVE | Chief Medical Officer |
Jul 01 '26 |
Sale |
12.86 |
36,725 |
472,284 |
213,009 |
| PAKOLA STEVE | Chief Medical Officer |
Jun 29 '26 |
Sale |
11.04 |
19,608 |
216,472 |
213,009 |
0.72%
1.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):